Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Neuroblastoma 1Lymphoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 344Rituximab 309Vincristine 159venetoclax 156Doxorubicin 156fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 110Dexamethasone 106Cytarabine 100ibrutinib 96Etoposide 94fludarabine phosphate 87Methotrexate 86acalabrutinib 80zanubrutinib 73Bendamustine Hydrochloride 72pembrolizumab 63blinatumomab 63CT-P10 61Gemcitabine 52glofitamab 45Nivolumab 45Calcium Dobesilate 45prednylidene 43Mercaptopurine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CUDC-907 × Lymphoid × 1 year × Clear all
NCT02909777 2026-02-11

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Dana-Farber Cancer Institute

Phase 1 Completed
26 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡